Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round, bringing total investments in the firm to $195 million. The round follows a $35 million Series A led by OrbiMed and Creacion Ventures. Investors in the latest round include Boyu Capital, Sequoia China, OrbiMed, and Creacion Ventures.
Financing and Operations
Frontera plans to use the funds to advance its gene therapy pipeline, including lead candidate FT-001. The company operates R&D facilities in Massachusetts, an operation center in Shanghai, and a manufacturing site in Suzhou, with a 2×2,000L reactor capacity via its APEX Technology & Manufacturing platform.
IND Filing for FT-001
Frontera has filed an investigational new drug (IND) application with the U.S. FDA for FT-001, a gene therapy targeting a rare inherited eye disease causing severe vision loss. Trial specifics remain undisclosed.-Fineline Info & Tech
